Ascentage Pharma Group Stock Today
| ASPHF Stock | USD 5.83 0.41 7.56% |
Performance10 of 100
| Odds Of DistressOver 52
|
Ascentage Pharma is trading at 5.83 as of the 24th of January 2025. This is a 7.56 percent up since the beginning of the trading day. The stock's lowest day price was 5.83. Ascentage Pharma has 52 percent odds of going through some form of financial distress in the next two years but had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 25th of November 2024 and ending today, the 24th of January 2025. Click here to learn more.
Moving against Ascentage Pink Sheet
Valuation
Check how we calculate scores
Ascentage Pink Sheet Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Ascentage Pharma Group [ASPHF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ascentage Pharma's market, we take the total number of its shares issued and multiply it by Ascentage Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ascentage Pharma classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 287.77 M outstanding shares.
Ascentage Pharma generates negative cash flow from operations
Check Ascentage Pharma Probability Of Bankruptcy
Ownership AllocationAscentage Pharma holds a total of 287.77 Million outstanding shares. Ascentage Pharma Group retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Ascentage Ownership Details
Ascentage Pharma Risk Profiles
| Mean Deviation | 5.11 | |||
| Standard Deviation | 18.39 | |||
| Variance | 338.3 | |||
| Risk Adjusted Performance | 0.1208 |
Ascentage Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Ascentage Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Ascentage Pharma Corporate Management
| Shaomeng Wang | Chairman CoFounder | Profile | |
| Jianfeng Wen | VP Science | Profile | |
| Yiqing Chen | Chief Officer | Profile | |
| Yifan MD | Chief Officer | Profile | |
| Raymond Kmetz | Chief Officer | Profile | |
| Gang Zhu | Chief Officer | Profile | |
| Dajun Yang | Chairman CoFounder | Profile |
Other Information on Investing in Ascentage Pink Sheet
Ascentage Pharma financial ratios help investors to determine whether Ascentage Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascentage with respect to the benefits of owning Ascentage Pharma security.